|January 7, 2013|
|09:55 EDT||ASTM, STEM, GERN, OSIR, BTX, CUR||Supreme Court turns down appeal over stem cell research, SCOTUSblog says|
The Supreme Court turned down an appeal by scientists seeking to stop all studies on embryonic stem cells, according to SCOTUSblog. The Fly notes that companies engaged in the research, development, and commercialization of stem cell therapies include StemCells (STEM), Neuralstem (CUR), Aastrom Biosciences (ASTM) and Osiris Therapeutics (OSIR). Also, earlier this morning, BioTime (BTX) entered into an agreement to acquire the intellectual property, including patents and patent applications, and other assets related to Geron's (GERN) human embryonic stem cell programs. Reference Link
News For STEM;CUR;OSIR;ASTM;BTX;GERN From The Last 14 Days
|December 1, 2015|
|07:47 EDT||GERN||Piper Jaffray to hold a conference|
Subscribe for More Information
|November 30, 2015|
|15:53 EDT||GERN||High option volume stocks|
High option volume stocks: BIG ZTS BLOX ARO AMRN GERN QUNR DECK ASNA THLD
|11:06 EDT||OSIR||Osiris recent selloff overdone, says Piper Jaffray|
Piper Jaffray analyst Edward Tenthoff says shares of Osiris Therapeutics have overreacted to the company's revenue restatement. The selloff is overdone and the valuation is attractive at current levels, Tenthoff tells investors in a research note. He views the revenue changes as small compared to total BioSurgery sales. Tenthoff reiterates an Overweight rating on Osiris with a $28 price target.
|November 24, 2015|
|07:17 EDT||STEM||StemCells coverage assumed with a Buy at H.C. Wainwright|
H.C. Wainwright analyst Yi Chen assume coverage on StemCells with a Buy rating and $2.10 price target.
|November 20, 2015|
|16:41 EDT||OSIR||Osiris to restate certain financial statements|
Osiris Therapeutics previously disclosed in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 that it had undertaken a review of the timing of revenue recognition under contracts with its distributors. As a result of this review, the Company determined to correct the revenue recognition for three contracts, which resulted in a decrease in product revenues of $1.8M in the first quarter of 2015, a decrease in product revenues of $1M in the second quarter of 2015, an increase in product revenues of $0.8M in the third quarter of 2015 and a decrease in product revenues of $1.1M in 2014. Each of these transactions are net of applicable cost of sales. These corrections were reflected in the Third Quarter 2015 Form 10-Q filed with the SEC on November 16, 2015. While the impact of these modifications to the Company's revenue recognition practices for certain distribution contracts is immaterial to its annual financial statements for the year ended December 31, 2014, the impact on the quarterly periods ending March 31, 2015 and June 30, 2015 is material. As a result, the Company will restate its previously issued interim financial statements for first quarter and second quarter of 2015 through the filing of amended Quarterly Reports on Form 10-Q for the quarters ended March 31, 2015 and June 30, 2015. These amended quarterly reports will be filed with the SEC as soon as administratively possible. On November 16 2015, management of the Company, in consultation with the Audit Committee of the Board of Directors and the Company's independent registered public accounting firm, concluded that investors should no longer rely on the Company's previously issued financial statements for the quarterly periods ended March 31, 2015 and June 30, 2015 and on any prior earnings releases or other communications relating to such periods.
|November 19, 2015|
|09:16 EDT||STEM||On The Fly: Pre-market Movers |
UP AFTER EARNINGS: Keurig Green Mountain (GMCR), up 19%... Ctrip.com (CTRP), up 11.8%... salesforce.com (CRM), up 5.4%... Perry Ellis (PERY), up 4%. ALSO HIGHER: Celladon (CLDN), up 55.9% after signing a merger agreement with Eiger BioPharmaceuticals... StemCells (STEM), up 45.7% after Phase II Pathway Study data shows motor improvement in SCI patients... UniPixel (UNXL), up 36.1% after receiving an initial mass production order from a Japanese PC manufacturer... Anavex Life Sciences (AVXL), up 16% after announcing preparation of regulatory filings based on guidance from FDA... Plug Power (PLUG), up 3.7% after securing Colruyt Group as its next GenDrive fuel cell customer in Europe. DOWN AFTER EARNINGS: Stage Stores (SSI), down 14.7%... JinkoSolar (JKS), down 7.5%... Best Buy (BBY), down 5.2%... Semtech (SMTC), down 7.5%. ALSO LOWER: AMAG Pharmaceuticals (AMAG), down 8.4% after receiving a complete response letter from the FDA its application seeking approval for a single-dose vial of Makena... Titan International (TWI), down 8.3% after being downgraded to Sell from Neutral at Goldman... Sunedison (SUNE), down 5.5% after Reuters reported that Blackstone (BX) is not interested in SunEdison investment.
|November 18, 2015|
|16:09 EDT||STEM||StemCells Phase II Pathway Study data shows motor improvement in SCI patients|
StemCells announced that the six-month interim results for the first cohort in its ongoing Phase II Pathway Study in cervical spinal cord injury, or SCI, showed motor improvements in both strength and function. The assessment of motor function involved using tests of dexterity. Patients eligible for the study have complete loss of motor control below the level of injury, the most severe degree of SCI as defined by the American Spinal Injury Association Impairment Scale, or AIS. Clinicians used both ISNCSCI, or International Standards for Neurological Classification of Spinal Cord Injury, and GRASSP, or Graded Assessment of Strength Sensibility and Prehension, measures to establish a pre-transplant baseline for each patient and to assess post-transplant progress. This first cohort of the Pathway Study was designed to assess the safety, and preliminary signs of efficacy, of cell administration into the cervical cord and select the dose level for the 40-patient second cohort, a randomized, controlled and single-blinded arm of the trial, which is already underway. Based on six-month follow-up, for the first cohort, an overall pattern of motor improvement was detected in four of the six patients as measured by gains in both strength and function on the collective ISNCSCI and GRASSP outcomes.
|08:06 EDT||BTX||BioTime names Russell Skibsted as CFO, succeeding Robert Peabody|
Subscribe for More Information
|November 17, 2015|
|10:00 EDT||OSIR||On The Fly: Analyst Downgrade Summary|
Today's noteworthy downgrades include: Airgas (ARG) downgraded on valuation at KeyBanc... BHP Billiton (BHP) downgraded to Neutral from Buy at Clarksons Platou... Chesapeake (CHK) downgraded to Neutral from Buy at Sterne Agee CRT... ChipMOS (IMOS) downgraded to Equal Weight from Overweight at Morgan Stanley... Clovis (CLVS) downgraded to Neutral from Conviction Buy at Goldman... Cooper Companies (COO) downgraded to Market Perform from Outperform at Wells Fargo... Five Below (FIVE) downgraded to Neutral from Buy at Sterne Agee CRT... Grainger (GWW) downgraded to Underweight from Neutral at Atlantic Equities... Hess Corp. (HES) downgraded to Perform from Outperform at Oppenheimer... J Sainsbury (JSAIY) downgraded to Neutral from Buy at Citi... Kindred Biosciences (KIN) downgraded to Market Perform from Outperform at BMO Capital... Leju (LEJU) downgraded to Neutral from Buy at BofA/Merrill... Lombard Medical (EVAR) downgraded to Equal Weight from Overweight at Barclays... Osiris (OSIR) downgraded to Sell from Hold at Brean Capital... Polaris Industries (PII) downgraded on anemic ORV growth at Wedbush... SQM (SQM) downgraded to Hold from Buy at HSBC... Southwestern Energy (SWN) downgraded to Underperform from Neutral at Sterne Agee CRT... Starwood (HOT) downgraded to Outperform from Buy at CLSA... Urban Outfitters (URBN) downgraded to Hold from Buy at Cantor... WM Morrison (MRWSY) downgraded to Sell from Neutral at Citi... adidas (ADDDY) downgraded to Sector Perform from Outperform at RBC Capital... athenahealth (ATHN) downgraded to Underweight from Equal Weight at Barclays.
|09:15 EDT||OSIR||On The Fly: Pre-market Movers |
UP AFTER EARNINGS: Nuance (NUAN), up 9.1%... Cheetah Mobile (CMCM), up 7.7%... Eros International (EROS), up 12.8%... Home Depot (HD), up 3.1%...Wal-Mart (WMT), up 2.2%. ALSO HIGHER: Ocera Therapeutics (OCRX), up 14.8% after announcing Phase 1 study results for the company's oral formulation of OCR-002... Fitbit (FIT), up 2.4% after being upgraded to Buy from Neutral at BofA/Merrill. DOWN AFTER EARNINGS: Dicks Sporting Goods (DKS), down 15.4%... Urban Outfitters (URBN), down 12.8%. ALSO LOWER: Osiris Therapeutics (OSIR), up 25.5% after being downgraded to Sell from Hold at Brean Capital... Angie's List (ANGI), down 8.7% after board unanimously determines not to pursue IAC (IACI) proposal... Clovis Oncology (CLVS), down 4.1% after receiving downgrades from Goldman and WallachBeth... Chesapeake Energy (CHK), down 2.5% after being downgraded to Neutral from Buy at Sterne Agee CRT... Cooper Companies (COO), down 2% after being downgraded to Market Perform from Outperform at Wells Fargo.
|06:08 EDT||OSIR||Osiris downgraded to Sell from Hold at Brean Capital|
Brean Capital analyst Jason Wittes downgraded Osiris Therapeutics to Sell with an $8 price target. The stock closed yesterday down 33c to $13.98. The company's quarterly filing shows evidence of "aggressive accounting, particularly in regard to revenue recognition," Wittes tells investors in a research note. There are three restatements from distributor relationships, two in addition to the initial one management noted on the earnings conference call, the analyst contends.